Gadopentetate dimeglumine is a contrast medium for magnetic resonance imaging (MRI) of the body after intravenous administration. It is often used when viewing intracranial lesions with abnormal vascularity or abnormalities in the blood-brain barrier. Its paramagnetic property reduces the T1 relaxation time (and to some extent the T2 relaxation time) in NMR, which is the source of its clinical utility. In August 2007, INNOPHARMAX had been granted the product license from DOH to market GADOMNI^® in Taiwan.